254 related articles for article (PubMed ID: 22455586)
1. Chelating agents for the treatment of systemic iron overload.
Ma Y; Zhou T; Kong X; Hider RC
Curr Med Chem; 2012; 19(17):2816-27. PubMed ID: 22455586
[TBL] [Abstract][Full Text] [Related]
2. Chemical features of in use and in progress chelators for iron overload.
Nurchi VM; Crisponi G; Lachowicz JI; Medici S; Peana M; Zoroddu MA
J Trace Elem Med Biol; 2016 Dec; 38():10-18. PubMed ID: 27365273
[TBL] [Abstract][Full Text] [Related]
3. Design of iron chelators with therapeutic application.
Zhou T; Ma Y; Kong X; Hider RC
Dalton Trans; 2012 Jun; 41(21):6371-89. PubMed ID: 22391807
[TBL] [Abstract][Full Text] [Related]
4. Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Bernhardt PV
Dalton Trans; 2007 Aug; (30):3214-20. PubMed ID: 17893764
[TBL] [Abstract][Full Text] [Related]
5. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism.
Richardson DR; Ponka P
Am J Hematol; 1998 Aug; 58(4):299-305. PubMed ID: 9692394
[TBL] [Abstract][Full Text] [Related]
6. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Kontoghiorghes GJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
[TBL] [Abstract][Full Text] [Related]
7. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
[TBL] [Abstract][Full Text] [Related]
8. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
9. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
10. New developments in iron chelators.
Cunningham MJ; Nathan DG
Curr Opin Hematol; 2005 Mar; 12(2):129-34. PubMed ID: 15725903
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
12. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
13. Design of clinically useful iron(III)-selective chelators.
Liu ZD; Hider RC
Med Res Rev; 2002 Jan; 22(1):26-64. PubMed ID: 11746175
[TBL] [Abstract][Full Text] [Related]
14. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation: an update.
Sheth S
Curr Opin Hematol; 2014 May; 21(3):179-85. PubMed ID: 24504090
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Macromolecular Iron Chelators.
Bulbake U; Singh A; Domb AJ; Khan W
Curr Med Chem; 2019; 26(2):323-334. PubMed ID: 30182850
[TBL] [Abstract][Full Text] [Related]
17. Iron chelator research: past, present, and future.
Tam TF; Leung-Toung R; Li W; Wang Y; Karimian K; Spino M
Curr Med Chem; 2003 Jun; 10(12):983-95. PubMed ID: 12678671
[TBL] [Abstract][Full Text] [Related]
18. Synthetic and natural iron chelators: therapeutic potential and clinical use.
Hatcher HC; Singh RN; Torti FM; Torti SV
Future Med Chem; 2009 Dec; 1(9):1643-70. PubMed ID: 21425984
[TBL] [Abstract][Full Text] [Related]
19. Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology.
Kontoghiorghe CN; Kolnagou A; Kontoghiorghes GJ
Molecules; 2015 Nov; 20(11):20841-72. PubMed ID: 26610453
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Potential of Iron Chelators and Prochelators.
Jansová H; Šimůnek T
Curr Med Chem; 2019; 26(2):288-301. PubMed ID: 28933303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
